Using circulating tumor DNA as a novel biomarker to screen and diagnose hepatocellular carcinoma: A systematic review and meta‐analysis
Open Access
- 26 December 2019
- journal article
- review article
- Published by Wiley in Cancer Medicine
- Vol. 9 (4) , 1349-1364
Abstract
Purpose: A meta‐analysis was formulated to appraise the diagnostic accuracy of circulating tumor DNA (ctDNA) in hepatocellular carcinoma (HCC).Materials and Methods: We enrolled all relevant studies published until September 2019. Four primary subgroups were investigated: the subgroup of quantitative or qualitative analysis of ctDNA, the subgroup of Ras association domain family 1 isoform A (RASSF1A) methylation in ctDNA and the subgroup of the combined alpha‐fetoprotein (AFP) and ctDNA assay. We analyzed the pooled sensitivity (SEN), specificity (SPE), positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odds ratio (DOR), and summary receiver operating characteristic (SROC) as well as the area under the curve (AUC).Results: A total of 33 qualified articles with 4113 subjects were incorporated into our meta‐analysis. The combined SEN, SPE, and DOR in quantitative studies were 0.722 (95% confidence interval (95% CI): 0.686‐0.756), 0.823 (95% CI: 0.789‐0.854), 18.532 (95% CI: 8.245‐41.657), respectively, yielding an AUC of 0.880. For qualitative studies, the corresponding value was 0.568 (95% CI: 0.548‐0.587), 0.882 (95% CI: 0.867‐0.897), 10.457 (95% CI: 7.270‐15.040) and 0.787, respectively. Detection of RASSF1A methylation yielded an AUC of 0.841, with a SEN of 0.644 (95% CI: 0.608‐0.678) and a SPE of 0.875 (95% CI: 0.847‐0.900). AFP combined with ctDNA assay achieved an AUC of 0.944, with a SEN of 0.760 (95% CI: 0.728‐00.790) and a SPE of 0.920 (95% CI: 0.893‐00.942).Conclusion: Circulating tumor DNA displays a promising diagnostic potential in HCC. However, it is not independently sufficient and can serve as an assistant tool combined with AFP for HCC screening and detection.Keywords
Funding Information
- National Natural Science Foundation of China (81872473)
This publication has 68 references indexed in Scilit:
- Methylation profiling of serum DNA from hepatocellular carcinoma patients using an Infinium Human Methylation 450 BeadChipHepatology International, 2013
- Determinants of Serum Alpha-Fetoprotein Levels in Hepatitis C–Infected PatientsClinical Gastroenterology and Hepatology, 2012
- Quantitative analysis of multiple methylated genes in plasma for the diagnosis and prognosis of hepatocellular carcinomaExperimental and Molecular Pathology, 2011
- QUADAS-2: A Revised Tool for the Quality Assessment of Diagnostic Accuracy StudiesAnnals of Internal Medicine, 2011
- Clinicopathological significance of RASSF1A reduced expression and hypermethylation in hepatocellular carcinomaHepatology International, 2010
- The prognostic value of circulating plasma DNA level and its allelic imbalance on chromosome 8p in patients with hepatocellular carcinomaJournal of Cancer Research and Clinical Oncology, 2006
- High frequency of promoter hypermethylation of RASSF1A in tumor and plasma of patients with hepatocellular carcinomaLiver International, 2005
- Measuring inconsistency in meta-analysesBMJ, 2003
- How should meta‐regression analyses be undertaken and interpreted?Statistics in Medicine, 2002
- CEA, AFP and Other Potential Tumor MarkersCA: A Cancer Journal for Clinicians, 1975